S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Is It Time To Throw In The Towel On Gamestop?
Closing prices for crude oil, gold and other commodities
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Is It Time To Throw In The Towel On Gamestop?
Closing prices for crude oil, gold and other commodities
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Is It Time To Throw In The Towel On Gamestop?
Closing prices for crude oil, gold and other commodities
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Is It Time To Throw In The Towel On Gamestop?
Closing prices for crude oil, gold and other commodities
NASDAQ:SAGE

Sage Therapeutics - SAGE Stock Forecast, Price & News

$39.48
-1.16 (-2.85%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$38.97
$40.55
50-Day Range
$32.20
$43.61
52-Week Range
$27.36
$45.74
Volume
516,753 shs
Average Volume
626,493 shs
Market Capitalization
$2.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.07

Sage Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
28.5% Upside
$50.73 Price Target
Short Interest
Bearish
7.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
-0.16mentions of Sage Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.88) to ($8.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

191st out of 1,022 stocks

Pharmaceutical Preparations Industry

76th out of 499 stocks

SAGE stock logo

About Sage Therapeutics (NASDAQ:SAGE) Stock

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Stock News Headlines

Mizuho Securities Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
Brokerages Set Sage Therapeutics, Inc. (NASDAQ:SAGE) PT at $50.07
Sage Therapeutics Recent Insider Activity
What to know about Biogen's new CEO
Here are three things to know about Biogen's new CEO
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Company Calendar

Last Earnings
11/02/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAGE
Employees
471
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.73
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+26.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
13 Analysts

Profitability

Net Income
$-457,890,000.00
Net Margins
-7,895.27%
Pretax Margin
-7,895.27%

Debt

Sales & Book Value

Annual Sales
$6.31 million
Book Value
$29.35 per share

Miscellaneous

Free Float
56,638,000
Market Cap
$2.35 billion
Optionable
Optionable
Beta
1.18

Key Executives

  • Mr. Barry E. GreeneMr. Barry E. Greene (Age 59)
    Pres, CEO & Director
    Comp: $1.25M
  • Ms. Kimi E. Iguchi CPA (Age 60)
    CFO & Treasurer
    Comp: $621.17k
  • Dr. Albert J. Robichaud Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $661.68k
  • Mr. Christopher Benecchi (Age 50)
    Chief Bus. Officer
    Comp: $389.35k
  • Mr. Matt Lasmanis
    Chief Technology & Innovation Officer
  • Helen Rubinstein
    Investor Relations Officer
  • Ms. Anne Marie Cook Esq. (Age 60)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Erin E. Lanciani (Age 53)
    Chief People & Experience Officer
  • Dr. Amy Schacterle Ph.D.
    Sr. VP of R&D Strategy and Bus. Management
  • Dr. Jim Doherty Ph.D.
    Chief Devel. Officer













SAGE Stock - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price forecast for 2023?

13 analysts have issued twelve-month price targets for Sage Therapeutics' stock. Their SAGE share price forecasts range from $37.00 to $85.00. On average, they anticipate the company's share price to reach $50.73 in the next year. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2022?

Sage Therapeutics' stock was trading at $42.54 at the beginning of the year. Since then, SAGE stock has decreased by 7.2% and is now trading at $39.48.
View the best growth stocks for 2022 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our SAGE earnings forecast
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($2.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.84) by $0.37. The biopharmaceutical company earned $1.44 million during the quarter, compared to the consensus estimate of $2 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 32.76% and a negative net margin of 7,895.27%. During the same quarter in the previous year, the business earned ($2.03) earnings per share.

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.11%), Vanguard Group Inc. (8.05%), Bellevue Group AG (4.99%), State Street Corp (4.97%), Price T Rowe Associates Inc. MD (3.60%) and Dimensional Fund Advisors LP (1.81%). Insiders that own company stock include Albert Robichaud, Barry E Greene, Barry E Greene, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $39.48.

How much money does Sage Therapeutics make?

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $2.35 billion and generates $6.31 million in revenue each year. The biopharmaceutical company earns $-457,890,000.00 in net income (profit) each year or ($8.63) on an earnings per share basis.

How many employees does Sage Therapeutics have?

The company employs 471 workers across the globe.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.

This page (NASDAQ:SAGE) was last updated on 12/9/2022 by MarketBeat.com Staff